Occult hepatitis B mutations drive liver cancer growth via Akt mTOR pathway

Occult hepatitis B virus (OBI) infection presents a significant global health challenge, notoriously flying under the radar of standard viral screening while relentlessly driving the pathogenesis of hepatocellular carcinoma (HCC). A critical but poorly understood factor in OBI-related tumorigenesis is the frequent emergence of mutations in the HBV pre-S genomic region. While these mutations are known to correlate with advanced liver disease, the precise molecular mechanisms by which they hijack host cellular machinery to fuel unregulated tumor growth have remained largely elusive.

This new research, published in Genes & Diseases by researchers from National Center of Gerontology, Beijing Engineering Research Center of Laboratory Medicine and Peking Union Medical College, investigated the oncogenic capacity of specific OBI-associated pre-S mutations to uncover their role in aberrant cell proliferation.

Through rigorous in vitro molecular experiments utilizing constructed wild-type and mutated full-length HBV plasmids transfected into human hepatoma (Huh-7) cells, the researchers systematically evaluated cellular growth and cycle dynamics. The data revealed that specific OBI-associated pre-S mutations—namely E39K, D44N, N98T, H128R, and I161T—accelerate the G1/S phase transition of the cell cycle, leading to aggressive cellular proliferation.

Comprehensive protein analyses deciphered the underlying intracellular networks, demonstrating that these mutations aggressively up-regulate the expression of the large hepatitis B surface protein (LHBs). This excessive LHBs subsequently triggers a massive activation of the Akt/mTOR signaling cascade, which strongly up-regulates the cell cycle driver Cyclin D1 and its associated kinases CDK4 and CDK6. This targeted protein surge dismantles normal cellular checkpoints, unleashing uncontrolled cell division.

To directly counter these severe hyper-proliferative effects, the researchers explored the therapeutic potential of targeted kinase inhibitors. Remarkably, advanced cellular assays confirmed that administering the highly specific Akt inhibitor MK2206 or the mTOR inhibitor rapamycin successfully intercepted this malignant cascade, decisively suppressing the mutation-driven hyper-proliferation and arresting the cells back in the G0/G1 phase.

By chemically blocking the Akt/mTOR signaling axis, these targeted therapies stripped the mutated hepatoma cells of their oncogenic growth advantage, fundamentally shielding the liver cells from unchecked replication. While these comprehensive data robustly highlight the critical influence of OBI-associated pre-S mutations in regulating the cell cycle, additional clinical studies are necessary to translate these targeted interventions into human therapies.

In conclusion, elucidating the oncogenic role of the LHBs-Akt/mTOR/Cyclin D1 signaling network offers a powerful new strategy to combat OBI-related liver cancer. This significant finding directly positions specific Akt and mTOR inhibitors as highly compelling therapeutic candidates for the next generation of precision hepatocellular carcinoma treatments.